Victoria Blinder, MD

Assistant Attending Physician

Victoria Blinder, MD

Assistant Attending Physician

Office Phone

646-888-8216

Current Research Interests

Dr. Blinder’s main research interest is in ethnic disparities in survivorship outcomes among women treated for breast cancer. Dr. Blinder has conducted qualitative research on barriers to return to work among ethnically diverse breast cancer survivors in New York City. She is currently collaborating with colleagues at UCLA on a prospective longitudinal study of low-income uninsured or under-insured breast cancer survivors in California. The results of the first three years of follow-up were published in Cancer in 2012. Dr. Blinder received an American Cancer Society mentored research scholar grant in 2010 to conduct a multi-center study of ethnic differences in the impact of breast cancer on employment status, financial situation, and quality of life. This study is ongoing and is currently open at MSKCC and five community hospitals throughout New York City. She also received a career development award from the American Society of Clinical Oncology for her pilot work in this area. Additional research interests include patient-physician communication about treatment planning and survivorship as well as ethnic disparities in breast cancer care and the financial impact of breast cancer on economically disadvantaged populations.

Education

University of Michigan Medical School

Publications

Blinder V, Elul B, Winikoff B. Mifepristone-misoprostol medical abortion: Who will use it and why? American Journal of Obstetrics and Gynecology. 1998, 179(5):1376. [PubMed Abstract]

Blinder V, Roboz GJ. Hematopoietic growth factors in myelodysplastic syndromes. Current Hematology Reports. 2003, 2(6):453-458. [PubMed Abstract]

Blinder V, Chadburn A, Furman RR, Mathew S, Leonard JP. Improving outcomes for patients with Burkitt lymphoma and HIV. AIDS Patient Care and STDs, 2008, 22(3):173-185. [PubMed Abstract]

Blinder V, Fisher S. The role of environmental factors in the etiology of lymphoma. Cancer Investigation, 2008, 26(3):306-316. [PubMed Abstract]

Gold HT, Hall MJ, Blinder V, Schackman BR. Cost effectiveness of pharmacogenetic testing for UGT1A1 before irinotecan administration for metastatic colorectal cancer. Cancer 2009, 115(17):3858-3867. [PubMed Abstract]

Blinder VS, Patil S, Thind A, Diamant A, Hudis CA, Basch E, Maly RC. Return to work in low-income Latina and non-Latina white breast cancer survivors: A 3-year longitudinal study. Cancer 2011, Aug 25 [Epub ahead of print]. [PubMed Abstract]

Blinder VS, Murphy MM, Vahdat LT, Gold HT, de Melo-Martin I, Hayes MK, Scheff RJ, Chuang E, Moore A, Mazumdar M. Employment after a breast cancer diagnosis: A qualitative study of ethnically diverse urban women. Journal of Community Health 2011, Nov 23 [Epub ahead of print]. [PubMed Abstract]

Read more

  1. Blinder V, Elul B, Winikoff B. Mifepristone-misoprostol medical abortion: Who will use it and why? American Journal of Obstetrics and Gynecology 1998, 179(5):1376.

  2. Blinder V, Roboz GJ. Hematopoietic growth factors in myelodysplastic syndromes. Current Hematology Reports. 2003, 2(6):453-458.

  3. Blinder V, Milowsky M. Editorial comment. Journal of Urology. 2007, 177(1):89.

  4. Blinder V, Chadburn A, Furman RR, Mathew S, Leonard JP. Improving outcomes for patients with Burkitt lymphoma and HIV. AIDS Patient Care and STDs, 2008, 22(3):173-185.

  5. Blinder V, Fisher S. The role of environmental factors in the etiology of lymphoma. Cancer Investigation, 2008, 26(3):306-316.

  6. Gold HT, Hall MJ, Blinder V, Schackman BR. Cost effectiveness of pharmacogenetic testing for UGT1A1 before irinotecan administration for metastatic colorectal cancer. Cancer 2009, 115(17):3858-3867.

  7. Blinder VS, Murphy MM, Vahdat LT, Gold HT, de Melo-Martin I, Hayes MK, Scheff RJ, Chuang E, Moore A, Mazumdar M. Employment after a breast cancer diagnosis: A qualitative study of ethnically diverse urban women. Journal of Community Health 2012, 37(4):763-772.

  8. Blinder VS, Patil S, Thind A, Diamant A, Hudis CA, Basch E, Maly RC. Return to work in low-income Latina and non-Latina white breast cancer survivors: A 3-year longitudinal study. Cancer 2012, 118(6):1664-1674.

  9. Ito K, Blinder V, Elkin E. Cost-effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer. Journal of Clinical Oncology 2012, 30(13):1468-1475.

  10. Haile RW, John E, Unger J, Cortessi, Gonzales M, Thompson P, Tucker KI, Ho G, Bondy M, Martinez E, Cook L, Cruz M, Wright J, Schwartz S, Blinder V, Hayes RB, Friedman Jimenez G, Monroe K, Thomas D, Boffetta P. A Review of Cancer in US Hispanic Populations. Cancer Prevention Research 2012;5(2):150-163.

  11. Blinder V. Disparities in Breast Cancer Outcomes: Receipt of Chemotherapy is Only Part of the Story. Journal of Clinical Oncology, 2012, 30(25):3041-3043.

  12. Partridge AH, Norris VW, Blinder VS, Cutter BA, Halpern MT, Malin J, Neuss MN, Wolff AC. Implementing a Breast Cancer Registry and Treatment Plan/Summary Program in Clinical Practice: An ASCO Pilot Program. Cancer 2013, 119(1): 158-163.

  13. Blinder VS, Norris VW, Peacock NW, Griggs JJ, Harrington DP, Moore A, Theriault RL, Partridge AH on behalf of the ASCO Breast Cancer Registry Pilot Steering Group. Patient Perspectives on Breast Cancer Treatment Plan and Summary Documents in Community Oncology Care: A Pilot Program. Cancer 2013, 119(1): 164-172.

Textbook Chapters

  1. Blinder V, Mazumdar M. Public policy issues in cancer rehabilitation. Principles and Practice of Cancer Rehabilitation, Editors: Michael Stubblefield, Michael O’Dell, Christian Custodio, and Teresa Fitzpatrick. Demos Medical Publishing, Woodbridge, CT, 2009.

  2. Elkin E, Blinder V. Advances in Breast Cancer: Reducing Risk and Improving Health Outcomes. Public Health in the 21st Century, Editor: Madelon L. Finkel. Praeger Publishing, Santa Barbara, CA, 2010.

My Events